Jinling Pharmaceutical: First Quarter Report of 2026
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
Securities code: 000919 Securities abbreviation: Jinling Pharmaceutical Announcement number: 2026-027
Jinling Pharmaceutical Co., Ltd.
2026 First Quarter Report
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:
The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the first quarter financial accounting report has been audited
□Yes ☑No
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
1. Main financial data
(1) Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes ☑No
Increases and decreases in this reporting period compared with the same period last year This reporting period compared with the same period last year
(%) Operating income (yuan) 768,671,414.38 810,013,922.67 -5.10% Net profit attributable to shareholders of listed companies
28,003,133.19 22,981,989.14 21.85% profit (yuan)
Deductions attributable to shareholders of listed companies
Net profit from non-recurring gains and losses 19,261,963.84 20,439,820.65 -5.76% (yuan)
Net cash flow from operating activities
-1,047,759.69 -57,763,324.07 98.19% amount (yuan)
Basic earnings per share (yuan/share) 0.0450 0.0370 21.62% Diluted earnings per share (yuan/share) 0.0450 0.0370 21.62% Weighted average return on equity 0.74% 0.60% 0.14% Increase or decrease at the end of this reporting period compared with the end of the previous year The end of the reporting period The end of the previous year
(%) Total assets (yuan) 6,016,268,786.47 6,006,812,960.30 0.16% owned by shareholders of listed companies
3,805,778,572.93 3,777,722,966.83 0.74% interest (yuan)
(2) Non-recurring profit and loss items and amounts
☑Applicable □Not applicable
Unit: Yuan
Item Amount for this reporting period Description
Gains and losses on disposal of non-current assets (including accrued
4,908,344.96
Offset portion of asset impairment provision)
Government subsidies included in current profits and losses (related to the company’s regular
Closely related to regular business operations and in compliance with national policies
2,473,704.22
stipulates, enjoys according to determined standards, and treats the company
Except for government subsidies that have a lasting impact on profits and losses)
Except for effective transactions related to the company’s normal business operations,
In addition to futures hedging business, non-financial enterprises hold financial
Changes in fair value of assets and financial liabilities 2,785,169.21
Profit and loss and disposal of financial assets and financial liabilities
profit and loss
Gains and losses from entrusting others to invest or manage assets 1,465,992.45 Income from financial products
Other non-operating income other than the above items and
-148,623.67
expenditure
Less: Income tax impact 1,512,937.95
Amount of impact on minority shareholders’ equity (after tax) 1,230,479.87
Total 8,741,169.35 --
Details of other profit and loss items that meet the definition of non-recurring profits and losses
□Applicable ☑Not applicable
The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items
□Applicable ☑Not applicable
The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.
(3) Changes in major accounting data and financial indicators and their reasons
☑Applicable □Not applicable
Unit: Yuan
Financial statement items Closing balance/beginning of the period to the end of the current period Balance at the end of the previous year/same period last year Year-on-year increase or decrease Reasons for changes
The main reason is that the subsidiary Meishan Hospital endorses receivable financing 7,911,956.22 1,500,000.00 427.46% and increases in the transferred notes receivable.
The main reason is other non-current assets held by the company for more than one year 273,318,639.43 181,650,798.03 50.46%
Due to the increase in time deposit certificates.
The main reason is that the company's advance payment for the current period is less rent received in advance 354,323.35 1,675,616.32 -78.85%
Caused by less.
The main reason is that the company's advance payment for goods in the current period increased contract liabilities 33,828,589.41 19,568,869.74 72.87%
Caused by addition.
The main reason is that the safety production expenses of the company's subsidiary Chizhou Dongsheng Special Reserve 195,341.22 142,868.31 36.73% increased compared with the same period last year.
The main reason is that the company's interest expenses for the current period increased financial expenses -995,562.35 -2,904,978.36 65.73%
In addition, due to the decrease in interest income.
The main reason is that the government's other income 2,473,704.22 1,567,564.36 57.81% subsidy received by the company in this period increased compared with the same period last year.
The main reason is that the investment income from the company's financial products in this period 3,820,402.61 9,392,399.03 -59.32%
The income for the period decreased compared with the same period last year.
The main reason is that the gain from changes in fair value of Zijin Bank's shares held by the company 2,785,169.21 -1,067,815.24 360.83% increased.
The main reason is the credit impairment loss of bad debt provisions accrued in the current period 295,342.39 -1,722,880.19 117.14%
Due to the decrease compared with the same period last year.
The main reason is that the income from asset disposal of the company's subsidiary Zhejiang Zhepan 4,908,344.96 -10,436.12 47132.28% is due to the increase in demolition compensation received by the company in the current period.
The main reason is that the company received default non-operating income in the current period 273,330.33 757,290.71 -63.91%
Due to the decrease in gold.
The main reason is that the company's non-current assets non-operating expenses in the current period 421,954.00 104,609.90 303.36%
Caused by increased damage and scrapping losses.
The main reason is that the company's cash generated from sales of goods and operating activities in the current period increased and cash received from providing services, purchases -1,047,759.69 -57,763,324.07 98.19%
Net flow is due to the decrease in cash paid for goods and services.
Net cash and cash equivalents Mainly due to the company’s current investment payment -307,677,685.79 -476,867,492.34 35.48%
The increase was due to the decrease in cash.
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Share Total number of common shareholders at the end of the reporting period 33,297 Total number of preference shareholders whose voting rights were restored at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Shareholding ratio Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Number of shares held
(%) Number of shares Share status Quantity Nanjing Xingong Investment
Group Limited Liability State-owned Legal Person 41.71% 259,390,380 0 Not applicable 0 Company
Fuzhou Investment Management
State-owned legal person 3.70% 23,003,700 0 Not applicable 0 Legal person limited company
Hefei Industrial Investment
Capital Holdings Co., Ltd. State-owned legal person 1.56% 9,711,271 0 Not applicable 0 companies
Zhejiang International Trade
Yi Group Co., Ltd. State-owned legal person 1.00% 6,224,865 0 Not applicable 0 company
#东永峰 Domestic natural person 0.80% 5,004,137 0 Not applicable 0 Si Youshan Domestic natural person 0.75% 4,687,200 0 Not applicable 0 #成grong Domestic natural person 0.51% 3,160,000 0 Not applicable 0 Goldman Sachs International - Since
Overseas legal person 0.44% 2,738,204 0 Not applicable 0 With funds
#陈国国 Domestic natural person 0.42% 2,632,500 0 Not applicable 0Pan Yuqiang Overseas natural person 0.34% 2,110,000 0 Not applicable 0Shareholdings of the top 10 unrestricted shareholders (excluding shares lent through refinancing and shares locked by executives)
Share type
Name of shareholder Number of shares without selling restrictions held
Type of shares Quantity Nanjing Xingong Investment Group Co., Ltd. 259,390,380 RMB ordinary shares 259,390,380 Fuzhou Investment Management Co., Ltd. 23,003,700 RMB ordinary shares 23,003,700 Hefei Industrial Investment Holding Co., Ltd. 9,711,271 RMB ordinary shares 9,711,271 Zhejiang International Trade Group Co., Ltd. 6,224,865 RMB common shares 6,224,865 #Dong Yongfeng 5,004,137 RMB common shares 5,004,137 Si Youshan 4,687,200 RMB common shares 4,687,200 #成grong 3,160,000 RMB common shares 3,160,000 Goldman Sachs International - Own funds 2,738,204 RMB ordinary shares 2,738,204 #陈国国 2,632,500 RMB ordinary shares 2,632,500 Pan Yuqiang 2,110,000 RMB ordinary shares 2,110,000
Among the top ten shareholders, Nanjing Xingong Investment Group Co., Ltd. is the controlling shareholder of the company. Explanation of related relationships or concerted actions among the above-mentioned shareholders. The company does not know whether other shareholders of non-restricted tradable shares are related or whether they are persons acting in concert.
Shareholder Dong Yongfeng holds 0 shares of the company in his ordinary securities account, and holds 5,004,137 shares in the company through his participation in margin trading and securities lending business through the customer credit transaction guarantee securities account of China Merchants Securities Co., Ltd., totaling 5,004,137 shares in the company. Shareholder Chengrong Ordinary Certificate
The securities account holds 0 shares of the company. Explanation on the participation of the top 10 shareholders in the margin trading and securities lending business through Caixin Securities Co., Ltd.’s customer credit (if any). The Yibao Securities account participates in the margin trading and securities lending business and holds 3,160,000 shares of the company, and holds a total of 3,160,000 shares of the company. Shareholder Chen Guomin holds 2,298,000 shares of the company in his ordinary securities account, and holds 334,500 shares in the company through margin trading and securities lending through the customer credit transaction guaranteed securities account of Shenwan Hongyuan Securities Co., Ltd., totaling 334,500 shares of the company.
The company has 2,632,500 shares.
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable ☑Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
□Applicable ☑Not applicable
(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
□Applicable ☑Not applicable
3. Other important matters
□Applicable ☑Not applicable
4. Quarterly Financial Statements
(1) Financial statements
- Consolidated balance sheet
Prepared by: Jinling Pharmaceutical Co., Ltd.
March 31, 2026
Unit: Yuan
Item Ending balance Beginning balance
Current assets:
Monetary funds 1,263,403,034.01 1,517,007,184.22Settlement reserves 0.00 0.00Lending funds 0.00 0.00Trading financial assets 1,213,197,614.46 939,314,534.86Derivative financial assets 0.00 0.00Notes receivable 223,405,933.87 281,333,848.64 Accounts receivable 510,739,861.84 408,116,907.89 Accounts receivable financing 7,911,956.22 1,500,000.00 Advance payment 6,639,716.35 6,245,643.03 Premiums receivable 0.00 0.00 Reinsurance accounts receivable 0.00 0.00 Reinsurance contract reserves receivable 0.00 0.00 Other receivables 5,620,053.70 5,424,318.18 Including: interest receivable 0.00 0.00
Dividends receivable 0.00 0.00 Financial assets purchased under resale agreements 0.00 0.00 Inventories 219,597,853.59 233,142,972.60
Including: Data resources 0.00 0.00 Contract assets 0.00 0.00 Assets held for sale 0.00 0.00 Non-current assets due within one year 289,897,789.17 393,026,213.81 Other current assets 11,372,936.36 12,636,357.06 Total current assets 3,751,786,749.57 3,797,747,980.29 Non-current assets:
Loans and advances 0.00 0.00 Debt investment 0.00 0.00 Other debt investments 0.00 0.00 Long-term receivables 0.00 0.00 Long-term equity investment 60,039,583.65 62,374,352.09 Other equity instrument investments 0.00 0.00 Other non-current financial assets 0.00 0.00 Investment real estate 7,306,253.26 7,542,654.79
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
Fixed assets 1,350,371,312.11 1,378,314,202.56 Construction in progress 51,617,481.07 48,161,902.57 Productive biological assets 580,031.25 613,751.58 Oil and gas assets 0.00 0.00 Right-of-use assets 29,082,123.04 29,949,477.22 Intangible assets 317,749,496.48 322,925,287.16
Among them: data resources 0.00 0.00 development expenditure 0.00 0.00
Including: Data resources 0.00 0.00Goodwill 44,373,040.70 44,373,040.70 Long-term deferred expenses 116,879,598.52 120,550,024.56 Deferred income tax assets 13,164,477.39 12,609,488.75 Other non-current assets 273,318,639.43 181,650,798.03 Total non-current assets 2,264,482,036.90 2,209,064,980.01 Total assets 6,016,268,786.47 6,006,812,960.30 Current liabilities:
Short-term borrowings 0.00 0.00 Borrowings from the central bank 0.00 0.00 Placement funds 0.00 0.00 Trading financial liabilities 0.00 0.00 Derivative financial liabilities 0.00 0.00 Notes payable 34,503,179.71 42,593,807.97 Accounts payable 509,153,480.91 512,376,871.41 Advances from customers 354,323.35 1,675,616.32 Contract liabilities 33,828,589.41 19,568,869.74 Financial assets sold and repurchased 0.00 0.00 Deposits from customers and interbank deposits 0.00 0.00 Securities trading agency funds 0.00 0.00 Agency underwriting of securities 0.00 0.00 Employee compensation payable 70,059,107.58 98,200,182.73 Taxes payable 56,379,039.87 58,622,439.15 Other payables 241,791,293.01 233,750,779.04Including: Interest payable 0.00 0.00
Dividends payable 2,240,000.00 2,917,251.40 Handling fees and commissions payable 0.00 0.00 Reinsurance accounts payable 0.00 0.00 Liabilities held for sale 0.00 0.00 Non-current liabilities due within one year 8,737,094.05 8,737,094.05 Other current liabilities 480,844.43 423,503.92 Total current liabilities 955,286,952.32 975,949,164.33 Non-current liabilities:
Insurance contract reserves 0.00 0.00 Long-term borrowings 150,097,916.67 150,097,916.67 Bonds payable 0.00 0.00 Including: Preferred shares 0.00 0.00
Perpetual bonds 0.00 0.00 Lease liabilities 33,337,143.71 32,980,748.82 Long-term payables 0.00 0.00 Long-term employee benefits payable 0.00 0.00 Estimated liabilities 0.00 0.00 Deferred income 602,106.46 681,968.48 Deferred income tax liabilities 25,128,019.14 25,009,886.31 Other non-current liabilities 0.00 0.00 Total non-current liabilities 209,165,185.98 208,770,520.28 Total liabilities 1,164,452,138.30 1,184,719,684.61 Owners’ equity:
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
Share capital 621,924,528.00 621,924,528.00 Other equity instruments 0.00 0.00 Among them: preference shares 0.00 0.00
Perpetual bonds 0.00 0.00 Capital reserves 1,088,273,942.59 1,088,273,942.59 Less: treasury shares 0.00 0.00 Other comprehensive income 2,512,226.61 2,512,226.61 Special reserves 195,341.22 142,868.31 Surplus reserve 425,449,851.55 425,449,851.55 General risk reserve 0.00 0.00 Undistributed profits 1,667,422,682.96 1,639,419,549.77 Total owners’ equity attributable to the parent company 3,805,778,572.93 3,777,722,966.83 Minority shareholders’ equity 1,046,038,075.24 1,044,370,308.86 Total owners’ equity 4,851,816,648.17 4,822,093,275.69 Total liabilities and owners’ equity 6,016,268,786.47 6,006,812,960.30 Legal representative: Chen Sheng Person in charge of accounting work: Wang Yang Person in charge of accounting department: Chang Ting
- Consolidated income statement
Unit: Yuan
Item Amount for the current period Amount for the previous period
Total operating income 768,671,414.38 810,013,922.67 Including: operating income 768,671,414.38 810,013,922.67 Interest income 0.00 0.00 Premiums earned 0.00 0.00 Fee and commission income 0.00 0.00
Total operating costs 747,885,190.74 788,644,161.76 Including: operating costs 603,324,751.58 653,156,391.47 Interest expenses 0.00 0.00 Handling fees and commission expenses 0.00 0.00 Insurance surrender charges 0.00 0.00 Net compensation expenses 0.00 0.00 Net withdrawal of insurance liability reserves 0.00 0.00 Policy dividend expense 0.00 0.00 Reinsurance fee 0.00 0.00 Taxes and surcharges 4,675,566.86 4,488,460.33 Sales expenses 25,803,258.94 22,006,480.98 Management expenses 89,193,023.54 90,715,196.32 Research and development expenses 25,884,152.17 21,182,611.02 Financial expenses -995,562.35 -2,904,978.36 Among them: interest expenses 1,237,644.89 922,117.21
Interest income 2,361,712.80 4,451,970.23 plus: other income 2,473,704.22 1,567,564.36 investment income (losses are filled in with "-"
3,820,402.61 9,392,399.03 columns)
Of which: for associates and joint ventures
739,588.66 1,402,568.56 Enterprise’s investment income
Measured at amortized cost
0.00 0.00 Income from derecognition of financial assets
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
Exchange gains (losses are filled in with "-"
0.00 0.00 column)
Net exposure hedging gain (loss calculated as
0.00 0.00 “-” (please fill in the column)
Gains from changes in fair value (losses calculated as
2,785,169.21 -1,067,815.24 (Fill in “-”)
Credit impairment losses (losses are marked with "-"
295,342.39 -1,722,880.19 fill in the column)
Asset impairment losses (losses are marked with "-"
0.00 0.00 fill in the column)
Asset disposal income (losses are marked with "-"
4,908,344.96 -10,436.12 fill in the column)
3. Operating profit (loss is filled in with "-"
35,069,187.03 29,528,592.75 columns)
Add: Non-operating income 273,330.33 757,290.71 Less: Non-operating expenses 421,954.00 104,609.90
4. Total profit (total loss is marked with "-"
34,920,563.36 30,181,273.56 fill in the column)
Less: Income tax expense 5,277,918.44 5,006,368.30
5. Net profit (net loss is filled in with "-"
29,642,644.92 25,174,905.26 columns)
(1) Classification by business continuity
- Net profit from continuing operations (net loss divided by
29,642,644.92 25,174,905.26 (Fill in “-”)
- Net profit from discontinued operations (net loss equal to
0.00 0.00 “-” (please fill in the column)
(2) Classification according to ownership ownership
Net profit attributable to owners of the parent company 28,003,133.19 22,981,989.14 2. Profit and loss of minority shareholders 1,639,511.73 2,192,916.12
Net after-tax amount of other comprehensive income 0.00 0.00 Other comprehensive income attributable to the owners of the parent company
0.00 0.00 net of tax
(1) Others that cannot be reclassified into profit or loss
0.00 0.00 Comprehensive income
- Remeasure changes in defined benefit plans
0.00 0.00 amount
- Others that cannot be transferred to profit or loss under the equity method
0.00 0.00 Comprehensive income
- Fair value of other equity instrument investments
0.00 0.00 change
- Fair value of the company’s own credit risk
0.00 0.00 change
5.Others 0.00 0.00
(2) Other comprehensive items that will be reclassified into profit or loss
0.00 0.00 combined income
- Other comprehensive items that can be transferred to profits and losses under the equity method
0.00 0.00 combined income
- Changes in fair value of other debt investments 0.00 0.00 3. Financial assets are reclassified and included in other comprehensive
0.00 0.00 Amount of total income
- Credit impairment provisions for other debt investments 0.00 0.00 5. Cash flow hedging reserves 0.00 0.00 6. Translation differences of foreign currency financial statements 0.00 0.00 7. Others 0.00 0.00 Other comprehensive income attributable to minority shareholders
0.00 0.00 Net after tax
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
- Total comprehensive income 29,642,644.92 25,174,905.26 Total comprehensive income attributable to owners of the parent company
28,003,133.19 22,981,989.14 amount
Total comprehensive income attributable to minority shareholders 1,639,511.73 2,192,916.12
8. Earnings per share:
(1) Basic earnings per share 0.0450 0.0370
(2) Diluted earnings per share 0.0450 0.0370 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: yuan, and the net profit realized by the merged party in the previous period is: yuan.
Legal representative: Chen Sheng Person in charge of accounting work: Wang Yang Person in charge of accounting department: Chang Ting
- Consolidated cash flow statement
Unit: Yuan
Item Amount for the current period Amount for the previous period
1. Cash flow generated from operating activities:
Cash received from selling goods and providing services 749,750,020.67 729,440,068.10 Net increase in customer deposits and deposits from banks 0.00 0.00
Net increase in borrowings from the central bank 0.00 0.00 Net increase in borrowing funds from other financial institutions 0.00 0.00 Cash received from premiums of the original insurance contract 0.00 0.00
Net cash received from reinsurance business 0.00 0.00
Net increase in policyholders’ savings and investment funds 0.00 0.00 Cash collected from interest, fees and commissions 0.00 0.00 Net increase in borrowing funds 0.00 0.00 Net increase in repurchase business funds 0.00 0.00 Net cash received from agency securities trading 0.00 0.00
Tax refunds received 0.00 0.00 Other cash received related to operating activities 13,437,298.45 19,429,576.97 Subtotal of cash inflows from operating activities 763,187,319.12 748,869,645.07 Cash paid for purchasing goods and receiving services 375,637,414.76 387,851,254.70
Net increase in customer loans and advances 0.00 0.00
Net increase in deposits with central banks and inter-banks 0.00 0.00
Cash used to pay compensation for the original insurance contract 0.00 0.00 Net increase in borrowed funds 0.00 0.00 Cash used to pay interest, fees and commissions 0.00 0.00 Cash used to pay policy dividends 0.00 0.00 Cash paid to and for employees 323,516,968.08 342,860,248.54 Various taxes paid 28,475,389.35 19,289,905.92 Other cash paid related to operating activities 36,605,306.62 56,631,559.98 Subtotal of cash outflows from operating activities 764,235,078.81 806,632,969.14Net cash flow generated from operating activities -1,047,759.69 -57,763,324.07
2. Cash flow generated from investing activities:
Cash received from recovery of investment 127,295,075.70 415,418,904.13 Cash received from investment income 1,988,519.99 5,824,825.52 Disposal of fixed assets, intangible assets and other long-term assets
6,569,011.00 Net cash amount recovered from assets in period 3,000.00
Received from disposal of subsidiaries and other business units
0.00 0.00 Net cash
Other cash received related to investing activities 0.00 0.00 Subtotal of cash inflow from investing activities 135,852,606.69 421,246,729.65 Purchase and construction of fixed assets, intangible assets and other long-term assets
9,574,584.72 80,308,521.92 Cash paid for assets
Jinling Pharmaceutical Co., Ltd. 2026 First Quarter Report
Cash paid for investment 431,343,089.73 759,127,273.67 Net increase in pledged loans 0.00 0.00 Cash paid for acquisition of subsidiaries and other business units
0.00 0.00 Net cash
Payment of other cash related to investing activities 0.00 0.00 Subtotal cash outflow from investing activities 440,917,674.45 839,435,795.59 Net cash flow generated from investing activities -305,065,067.76 -418,189,065.94
3. Cash flow generated from financing activities:
Cash received from investment 0.00 0.00 Including: subsidiary absorbs investment from minority shareholders
0.00 0.00 Cash received
Cash received from borrowings 0.00 0.00 Cash received from other financing activities 0.00 0.00 Subtotal of cash inflows from financing activities 0.00 0.00 Cash paid to repay debt 0.00 0.00 Distribution of dividends, profits or payment of interest
1,558,501.40 922,117.21 cash
Including: Payments made by subsidiaries to minority shareholders
677,251.40 0.00 Dividends, profits
Payment of other cash related to financing activities 0.00 0.00 Subtotal of cash outflows from financing activities 1,558,501.40 922,117.21 Net cash flow generated from financing activities -1,558,501.40 -922,117.21
4. The impact of exchange rate changes on cash and cash equivalents
-6,356.94 7,014.88 impact
Net increase in cash and cash equivalents -307,677,685.79 -476,867,492.34 plus: opening balance of cash and cash equivalents 1,361,103,616.77 1,581,367,967.42
Balance of cash and cash equivalents at the end of the period 1,053,425,930.98 1,104,500,475.08
(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2026
□Applicable ☑Not applicable
(3) Audit report
Whether the first quarter financial accounting report has been audited
□Yes ☑No
The company's first quarter financial accounting report has not been audited.
Board of Directors of Jinling Pharmaceutical Co., Ltd.